🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Markets · 15 min delay
NBI4,187.6â–˛ +1.14%
PFE28.42â–Ľ -0.38%
AZN74.18â–˛ +0.81%
NVO103.55â–˛ +2.07%
ROG261.40â–Ľ -0.55%
ABBV174.92â–˛ +0.29%
EUR/USD1.0842â–Ľ -0.12%
ISEQ9,241.3â–˛ +0.62%
NBI4,187.6â–˛ +1.14%
PFE28.42â–Ľ -0.38%
AZN74.18â–˛ +0.81%
NVO103.55â–˛ +2.07%
ROG261.40â–Ľ -0.55%
ABBV174.92â–˛ +0.29%
EUR/USD1.0842â–Ľ -0.12%

Search Results

Found 51 results for "industry" across articles, medicines, trials, companies and the glossary

Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots
Regulatory Affairs
Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots
The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.
24 hrs ago
AI Real Estate Pioneer Build Raises $8.5M Seed Round to Automate Infrastructure Workflows
MedTech
AI Real Estate Pioneer Build Raises $8.5M Seed Round to Automate Infrastructure Workflows
Build, a startup co-founded by James Stirrat-Ellis and Ben McClusky, has secured $8.5 million in seed funding led by Index Ventures to expand Dougie, its AI platform for real estate infrastructure workflows.
2 days ago
A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals
Regulatory Affairs
A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals
In a landmark world-first, Irish-founded Chanelle McCoy Health has received official regulatory approvals from the Saudi Food and Drug Authority and confirmation of safety under EU Novel Food guidelines for its Pureis® Ultra Pure CBD range.
4 days ago
The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026
Regulatory Affairs
The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026
A comprehensive technical report detailing the top 10 trends in Good Manufacturing Practice (GMP), sterile manufacturing, GAMP 5, Quality 4.0, and continuous manufacturing currently reshaping the global pharmaceutical landscape.
5 days ago
Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs
Industry
Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs
An in-depth analysis of two newly opened funding opportunities—Women TechEU and Innovate UK's Next Wave Createch—designed to support early-stage deep tech and creative technology innovators across Europe and the UK.
6 days ago
FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings
Regulatory Affairs
FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings
The FDA has issued a formal warning letter to Sanofi's Waterford facility, Genzyme Ireland Limited, citing data integrity breaches, discarded quality records, and botched deviation investigations in the production of haemophilia drug Altuviiio and transplant therapy Thymoglobulin.
6 days ago
Master's in Pharmacy & Pharmaceutical Sciences in Ireland: Complete 2026 Guide for International Students
Pharmaceutical
Master's in Pharmacy & Pharmaceutical Sciences in Ireland: Complete 2026 Guide for International Students
An exhaustive guide detailing postgraduate Level 9 pharmaceutical master's programs across Irish universities, covering tuition fees, eligibility criteria, and requirements for international applicants.
29 Jun 2026
ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers
Clinical Trials
ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers
The annual ASCO conference has delivered landmark clinical trial results, bringing promising survival extensions for pancreatic cancer and targeted lung cancer therapies.
29 Jun 2026
From Pilots to Infrastructure: How AI is Becoming the Core Operating System for Biopharma R&D in 2026
MedTech
From Pilots to Infrastructure: How AI is Becoming the Core Operating System for Biopharma R&D in 2026
Artificial intelligence has evolved from sandbox pilot projects to become the default operating system driving drug discovery, clinical trials, and sterile manufacturing.
29 Jun 2026
Global Biopharma M&A Rebounds in 2026: AbbVie and Merck KGaA Lead Multi-Billion Dollar Acquisitions
Industry
Global Biopharma M&A Rebounds in 2026: AbbVie and Merck KGaA Lead Multi-Billion Dollar Acquisitions
Global pharmaceutical dealmaking has surged in 2026 as cash-rich majors AbbVie and Merck KGaA close multi-billion dollar acquisitions to restock pipelines ahead of late-decade patent cliffs.
29 Jun 2026
Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions
Industry
Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions
Explore the highest-ranked Irish universities, including Trinity College Dublin, UCD, UCC, and University of Galway, looking at their global ranking positions, location, and key research strengths.
28 Jun 2026
Life Science PR in 2026: The Complete Guide to Building Authority, Winning Media Coverage, and Controlling Your Narrative
Biotechnology
Life Science PR in 2026: The Complete Guide to Building Authority, Winning Media Coverage, and Controlling Your Narrative
A definitive 5,000-word guide to public relations for pharmaceutical, biotech, and MedTech professionals. Learn how to build a PR strategy from scratch, which tools to use, how to write for journalists and LinkedIn, and the exact frameworks used by the world's leading life science communications teams.
27 Jun 2026
LinkedIn PR for Life Science & Pharma: The Definitive Guide to Building Credibility, Authority, and Visibility in 2026
LinkedIn
LinkedIn PR for Life Science & Pharma: The Definitive Guide to Building Credibility, Authority, and Visibility in 2026
A practitioner-level guide to building genuine professional authority on LinkedIn as a pharmaceutical, biotech, or MedTech professional. Covers profile architecture, content strategy, engagement tactics, thought leadership frameworks, and the exact playbooks used by the most followed life science voices on the platform.
27 Jun 2026
UK Looks to Spain’s "Catalonia Blueprint" to Boost Global Clinical Trials Competitiveness
Regulatory Affairs
UK Looks to Spain’s "Catalonia Blueprint" to Boost Global Clinical Trials Competitiveness
As global competition intensifies, UK life sciences leaders are examining Spain’s thriving Catalonia region for strategies to attract commercial sponsors, streamline regulatory reviews, and revitalize Britain’s clinical trials sector.
25 Jun 2026
Pharmaceutical Regulatory Update 2026: EU, UK, FDA & Global Changes Explained
Regulatory Affairs
Pharmaceutical Regulatory Update 2026: EU, UK, FDA & Global Changes Explained
A massive wave of regulatory reform is sweeping the global pharma industry in 2026. From the EU's most significant legislative overhaul in decades to the FDA's sweeping Operation TrialBlazer, we break down what quality, manufacturing, and regulatory teams need to know to stay compliant.
25 Jun 2026
From Farming to Pharma: The History of Ireland’s Life Sciences Revolution
Biotechnology
From Farming to Pharma: The History of Ireland’s Life Sciences Revolution
How did a nation once defined by agriculture and emigration transform into the world’s third-largest exporter of pharmaceuticals? We trace the deliberate policy shifts, educational reforms, and FDI strategies that built Ireland’s booming life sciences ecosystem.
25 Jun 2026
Navigating Ireland’s Pharma Dependency: Strategies for Policy and Talent in an Uncertain Era
Industry
Navigating Ireland’s Pharma Dependency: Strategies for Policy and Talent in an Uncertain Era
With pharmaceuticals making up 20% of Ireland’s GDP, the nation’s reliance on the industry brings immense economic benefit but notable risks. We explore how Ireland must adapt its policy, manage geopolitical headwinds, and aggressively attract skilled labour to secure its future.
25 Jun 2026
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Regulatory Affairs
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.
25 Jun 2026
Egypt, Ireland Explore Industrial Cooperation in Pharmaceuticals, Renewable Energy, and Advanced Technologies
Industry
Egypt, Ireland Explore Industrial Cooperation in Pharmaceuticals, Renewable Energy, and Advanced Technologies
Egypt’s Minister of Industry and Ireland’s Ambassador discuss strategic collaboration across pharmaceuticals, renewable energy, and technology sectors, aiming to leverage Irish expertise for local manufacturing.
25 Jun 2026
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
Clinical Trials
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.
25 Jun 2026
Viewpoint: Why Ireland’s Pharma Sector is Immune to the Global 'Carbon Leakage' Exodus
Industry
Viewpoint: Why Ireland’s Pharma Sector is Immune to the Global 'Carbon Leakage' Exodus
A new Central Bank of Ireland study reveals that while global manufacturers flee strict climate laws, Ireland's biopharma sector remains stubbornly rooted. Here is what this means for the future of Irish FDI.
25 Jun 2026
Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment
Clinical Trials
Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment
Helus Pharma announces a $50 million offering to progress Phase 3 trials for their novel serotonergic agonists, alongside major clinical milestones and leadership updates.
25 Jun 2026
Leading Digital Transformation in Ireland’s Pharma Sector: 5 Ways to Overcome Middle Management Resistance to AI
MedTech
Leading Digital Transformation in Ireland’s Pharma Sector: 5 Ways to Overcome Middle Management Resistance to AI
As Ireland’s pharma sector pivots toward Industry 4.0, middle management resistance to AI is a critical bottleneck. Here are 5 root causes of this pushback and targeted strategies to align your teams and drive digital transformation.
25 Jun 2026
Bridging the Gap: How WorkEqual is Empowering Women and Driving Workplace Equity in Ireland
Industry
Bridging the Gap: How WorkEqual is Empowering Women and Driving Workplace Equity in Ireland
An in-depth look at WorkEqual, its mission to help women (re)enter the Irish workforce, its national advocacy for gender parity, and the new WorkAbility Programme supporting people with disabilities.
23 Jun 2026
A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge
Biotechnology
A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge
An in-depth analysis of the massive wave of pharmaceutical mergers and acquisitions in the first half of 2026, driven by patent cliffs, pipeline replenishment, and high-growth therapeutic areas.
23 Jun 2026
The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments
Pharmaceutical
The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments
An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.
23 Jun 2026
LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance
LinkedIn
LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance
A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.
22 Jun 2026
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.
22 Jun 2026
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
LinkedIn
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.
22 Jun 2026
Global Biopharma Layoff Tracker Report (2025–2026): A Structural Reshaping
Biotechnology
Global Biopharma Layoff Tracker Report (2025–2026): A Structural Reshaping
A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.
22 Jun 2026
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Pharmaceutical
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.
22 Jun 2026
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
22 Jun 2026
Eisai Allocates ÂŁ48M to UK Cold-Chain Pharma Packaging Hub
Pharmaceutical
Eisai Allocates ÂŁ48M to UK Cold-Chain Pharma Packaging Hub
Japanese pharmaceutical company Eisai announces a ÂŁ48 million investment at its Hatfield, UK site to establish advanced cold-chain supply and packaging capabilities, supported by the Life Sciences Innovative Manufacturing Fund.
22 Jun 2026
Beyond the Strait: How the US-Iran Peace Deal Will Reshape Ireland’s Pharmaceutical Value Chains in 2026
Industry
Beyond the Strait: How the US-Iran Peace Deal Will Reshape Ireland’s Pharmaceutical Value Chains in 2026
With the US-Iran peace deal signed and the Strait of Hormuz set to reopen, Ireland's pharmaceutical export sector stands to benefit from stabilized global energy tariffs, normalized maritime trade corridors, and renewed multinational capital inflows.
21 Jun 2026
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
21 Jun 2026
Ireland Announces Major Updates to Employment Permit Occupation Lists
Industry
Ireland Announces Major Updates to Employment Permit Occupation Lists
A detailed analytical deep-dive into the Irish Government's 2026 updates to Critical Skills and General Employment Permit lists, reviewing quotas, key sectors, and the proposed changes to the 50:50 rule.
21 Jun 2026
AbbVie Nears $11 Billion Acquisition of Apogee Therapeutics to Bolster Immunology Pipeline
Industry
AbbVie Nears $11 Billion Acquisition of Apogee Therapeutics to Bolster Immunology Pipeline
AbbVie is reportedly in advanced negotiations to acquire clinical-stage biotech Apogee Therapeutics for approximately $10.9 billion in cash, aiming to secure the promising long-acting eczema therapy zumilokibart.
19 Jun 2026
Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland
Industry
Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland
Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.
18 Jun 2026
J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer
Clinical Trials
J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer
Japanese biotech J-Pharma and Ireland-based Uniphar have received FDA alignment to bypass Phase II and advance nanvuranlat (JPH203) directly into a pivotal global Phase III study for second-line biliary tract cancer.
18 Jun 2026
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Industry
Jazz Pharmaceuticals Strikes Strategic $820M Research Deal with AbCellera for Next-Gen T-Cell Engaging Antibodies
Discover how Jazz Pharmaceuticals and AbCellera are joining forces in a high-stakes, $820M biopharma collaboration to pioneer next-generation T-cell engaging (TCE) multispecific antibodies targeting gastrointestinal cancers and challenging solid tumors.
18 Jun 2026
The 47% Problem: Is the Irish Graduate Job Market Broken?
Industry
The 47% Problem: Is the Irish Graduate Job Market Broken?
A staggering 47% of Irish employers have slashed entry-level and graduate roles in 2026. What does this massive structural shift mean for the Class of 2025 and 2026, and how can graduates pivot to survive the "entry-level paradox"?
16 Jun 2026
Leading CDMO Companies in Ireland: Your Complete Guide to Contract Manufacturing in 2026
Pharmaceutical
Leading CDMO Companies in Ireland: Your Complete Guide to Contract Manufacturing in 2026
A comprehensive guide to the top CDMO companies in Ireland - from Hovione and Thermo Fisher in Cork to EirGen Pharma in Waterford and HiTech Health in Galway. Full profiles, capabilities, certifications, and facilities of Ireland's leading contract development and manufacturing organizations.
16 Jun 2026
Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules
Regulatory Affairs
Breckenridge Pharmaceutical Issues Major Recall for Duloxetine Capsules
Breckenridge Pharmaceutical has initiated a voluntary recall of hundreds of thousands of bottles of Duloxetine Delayed-Release Capsules due to the presence of nitrosamine impurities exceeding FDA limits.
16 Jun 2026
Enterprise Ireland Reports Record €38.86bn in Exports: What It Means for Indigenous Life Sciences
Pharmaceutical
Enterprise Ireland Reports Record €38.86bn in Exports: What It Means for Indigenous Life Sciences
Enterprise Ireland has announced record total exports of €38.86 billion. With the Advanced Manufacturing and Life Sciences sector surging by 14% to €13.16 billion, we analyse what this means for Ireland's homegrown pharma ecosystem.
16 Jun 2026
Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing
Regulatory Affairs
Consumer Watchdog Launches Major Probe into Retail Pharmacy Sector Pricing
The Competition and Consumer Protection Commission (CCPC) has launched a comprehensive market study into Ireland's retail pharmacy sector, targeting opaque pricing practices and a lack of competition.
16 Jun 2026
The European Biotech Act 2026: A Catalyst for Competitiveness and Innovation in Health Biotechnology
Biotechnology
The European Biotech Act 2026: A Catalyst for Competitiveness and Innovation in Health Biotechnology
The European Commission has proposed the European Biotech Act to turbocharge the EU's health biotechnology sector, streamline regulations, and regain global competitiveness against the US and China.
16 Jun 2026
Avectas: Engineering the Future of Cell Therapy Manufacturing
Pharmaceutical
Avectas: Engineering the Future of Cell Therapy Manufacturing
Recognizing the critical industry bottleneck in scalable cell therapy production, Avectas has announced a landmark collaboration with CCRM and OmniaBio to evaluate its innovative manufacturing platform.
16 Jun 2026
How to Create a LinkedIn Profile Using AI: The 2026 Guide for Life Science Professionals
LinkedIn
How to Create a LinkedIn Profile Using AI: The 2026 Guide for Life Science Professionals
Step-by-step guide to building a standout LinkedIn profile using ChatGPT and AI tools - written for pharma, biotech, and MedTech professionals in Ireland. Includes copy-paste AI prompts for every section.
15 Jun 2026
Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029
Regulatory Affairs
Landmark Agreements on Medicine Pricing and Supply Target 180-Day Turnaround by 2029
The Irish government signs major new Framework Agreements with MFI and IPHA, aiming to reduce patient wait times for innovative treatments to 180 days by 2029.
15 Jun 2026
Rare Disease Bottlenecks vs. Encouraging Clinical Trial Growth in Ireland
Biotechnology
Rare Disease Bottlenecks vs. Encouraging Clinical Trial Growth in Ireland
Despite encouraging growth in clinical trial activity, patients in Ireland face an average wait of 801 days for access to rare disease medicines, prompting calls for urgent systemic reform.
15 Jun 2026